ASX:IMMPharmaceuticals, Biotechnology & Life SciencesBiotechnology
Immutep Ltd
$0.054
$0.001 (0.93%)
Day Range
$0.053 – $0.054
52 Week Range
$0.028 – $0.470
Volume
282.83K
Avg Volume (10D)
5.66M
Market Cap
$78.84M
Price Chart
OHLC · volume · moving averages
$0.054-$0.332 (-86.10%)over 6M
Hi$0.400Lo$0.028Avg Vol27.9M
Price-sensitive newsVolumePrev close · 52W rangeDrag the handles below to zoom
Market Statistics
Today's trading range
Open
$0.053
Previous Close
$0.054
Day High
$0.054
Day Low
$0.053
52 Week High
$0.470
52 Week Low
$0.028
Valuation
Fundamental multiples
Market Cap
78.84M
Shares Outstanding
1.47B
Price to Book
0.79
Trading Activity
Volume & order book
Volume
282.83K
Value Traded
15.10K
Bid
$0.053 × 439,992
Ask
$0.054 × 1,521,602
Performance
Returns across timeframes
1 Day
0.00%
5 Day
1.92%
13 Week
-7.02%
52 Week
-79.22%
YTD
-87.23%
Technical Indicators
Momentum & moving averages
RSI (14)
56.51
50-Day SMA
$0.051
200-Day SMA
$0.186
— From the desk
Latest News
Hot Topics
Weekly Wrap: Shares fall another 2.6% for the week as conflict worsens
ASX 200 slides 2.6% this week to 8,617 as Iran-Israel conflict lifts oil above $100; NST and SYR plunge, while EOS soars on a Middle East contract.
Biotechnology
Immutep doses first patient in Phase II/III efti trial to treat metastatic breast cancer
Biotechnology company Immutep (ASX: IMM) has safely dosed the first patient at a European clinical site for its integrated Phase II/III AIPAC-003 trial to treat metastatic breast cancer. AIPAC-003 is evaluating the company’s soluble LAG-3 protein and first-in-class MHC Class II agonist known as eftilagimod alpha (efti) in combination with standard-of-care paclitaxel for the treatment […]